Providers / NexLife

NexLife review — compounded semaglutide & tirzepatide programs

Verdict

Quick facts

The table rows further down carry the full plan-by-plan figures; the facts below summarize the program structure as captured on 2026-07-20. Every entry is provider-reported unless labeled otherwise.

Medications

compounded semaglutide, compounded tirzepatide (not FDA approved)

Dosage forms

subcutaneous injection; ODT/sublingual tablets

Program types

standard-dose and "microdose" plans, each in 1/3/6/12-month terms

Membership fee

None reported

Dose surcharges

None reported — "flat pricing at every dose"

Shipping

Free expedited, reported

Pharmacy model

Five conditionally named partner pharmacies; per-order identity unconfirmed

Evidence status

PROVIDER REPORTED — checkout capture pending

Current status

Status: Active but evidence incomplete. NexLife's program pages were live and consistent with the captured pricing as of 2026-07-20. Regulatory-history verification against FDA, FTC, and state-board sources is scheduled but not yet complete, so no regulatory-history conclusion — favorable or unfavorable — is published for NexLife at this time. The record moves to "Active and verified" only after checkout capture and those registry checks conclude.

Company and clinical model

NexLife markets itself as a telehealth platform for weight management and metabolic health built around a care model it brands "Care360," which it describes as including provider oversight, follow-up, behavioral support, nutrition guidance, and care coordination. The clinical pathway it describes is fully online: a medical intake reviewed by a U.S.-licensed provider, prescription when the provider deems treatment appropriate, pharmacy fulfillment, and remote monitoring, with adults at BMI 27 or higher described as potentially eligible.

Three of its trust claims deserve explicit labeling. "LegitScript-certified" and "works exclusively with LegitScript-certified, NABP-accredited pharmacies" are provider statements pending registry confirmation. "Every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels" is a provider statement with no test documentation reviewed by us. And the weight-loss figures in its marketing — an average of 15% with weekly semaglutide and up to 24.3% with tirzepatide — come from clinical trials of FDA-approved injections; they are not outcomes evidence for NexLife's compounded products. NexLife also cites self-reported data from 111 members averaging 29 lb lost over six months, which is uncontrolled, self-selected, and not clinical evidence. No claim in this paragraph should be repeated as verified fact.

Who NexLife may suit

On captured structure, NexLife fits a specific shopper: someone comparing compounded programs on total cost who wants the advertised price to be the whole price. Because no membership fee, no dose surcharges, and free shipping are reported, a $165 month-to-month semaglutide plan should cost $165 — a genuine contrast with membership models where a $99 headline becomes $178 after fees. It may also suit people who expect to titrate upward and want price certainty across doses, and disciplined long-term users comfortable prepaying for a lower effective rate, provided they first confirm refund terms and beyond-use-date coverage on advance shipments.

Who should consider another provider

Anyone who needs verified renewal pricing, cancellation mechanics, or availability in their state today should wait or look elsewhere, because none of those are captured yet. Anyone eligible for FDA-approved products through insurance, or priced into manufacturer cash-pay channels such as LillyDirect or NovoCare, should price those first — they carry premarket-reviewed manufacturing that no compounded product has, and we never rank the two classes together. Anyone who wants to know the exact dispensing pharmacy before paying should note that NexLife names five possible partners conditionally rather than confirming one per order. And anyone drawn by the "microdose" or ODT programs should read the evidence limitations below: neither format inherits the trial results of standard-dose approved injections.

Programs and pricing, captured 2026-07-20

Six program families were captured, each in four plan lengths. Standard-dose and microdose programs are different products and are analyzed separately, as are injections and ODT/sublingual tablets. Prepaid multi-month plans are labeled: a monthly equivalent is arithmetic, not a billing schedule, and the full plan price is due up front.

Standard semaglutide injection

The month-to-month plan is $165. Prepaying compresses the effective rate: $447 over three months ($149.00/month), $882 over six ($147.00), and $1,740 over twelve ($145.00). The absolute saving for locking up $1,740 for a year versus paying monthly is $240 — about 12% — so the prepay decision is really a bet on staying in treatment twelve months and on the refund policy, which is unverified. Because no membership or dose surcharge is reported, these figures should equal the all-in cost if checkout confirms them; that conditional is the reason this program remains Provider Reported rather than Verified.

Standard tirzepatide injection

Month-to-month is $215; prepaid terms run $585/3-month ($195.00), $1,140/6-month ($190.00), and $2,232/12-month ($186.00). The 12-month commitment saves $348 versus monthly billing — again roughly 13% — with $2,232 due up front. The same all-inclusive caveat applies, and so does the same comparison discipline: tirzepatide figures are never ranked against semaglutide figures, because they are different medications with different captured price floors.

Semaglutide microdose

NexLife's microdose semaglutide is captured at $129 monthly, with prepaid terms at $684/6-month and $1,320/12-month ($114.00 and $110.00/month effective); the 3-month plan's total and advertised monthly are under recapture per the note above. The larger caveat is clinical, not arithmetic: "microdose" has no standardized definition, and sub-therapeutic dosing has no equivalent trial base. A lower price for an unproven dose regimen is not a bargain by default.

Tirzepatide microdose

Monthly is captured at $189 and the 12-month term at $1,764 ($147.00/month effective). The 3-month and 6-month totals are under recapture: an external review reports current-page values of $477 (3-month) and $900 (6-month), conflicting with our prior capture of $479 and $899, so the effective monthly equivalents for those two terms are suppressed pending a fresh single-source capture (ledger EV-0022). The microdose evidence caveat above applies in full, and no microdose savings ranking is published while these figures are unresolved.

Semaglutide ODT / sublingual

Monthly is $199, with prepaid terms of $597, $1,062, and $1,980 — effective rates of $199.00, $177.00, and $165.00. One captured claim fails arithmetic: the 3-month plan advertised a $42 saving, but three monthly payments of $199 equal exactly $597, demonstrating no saving at all. That field is stored as Conflicting Evidence (EV-0003), excluded from every savings comparison, and suppressed on this site until the checkout price and terms are verified. The formulation caveat is separate and larger: no compounded ODT or sublingual semaglutide has FDA-reviewed absorption or efficacy data, and evidence from Rybelsus — an approved oral tablet with a specific absorption-enhancer formulation — does not transfer.

Tirzepatide ODT / sublingual

Monthly is $229; prepaid terms are $657/3-month ($219.00), $1,230/6-month ($205.00), and $2,388/12-month ($199.00), with advertised savings of $30, $144, and $360 that are internally consistent with the totals. The evidence position is weaker still than the semaglutide ODT: there is no FDA-approved oral tirzepatide at all, so no approved-product analogue even exists to be mistaken for equivalent.

Effective monthly cost, worked

Our formula is total mandatory cost for the period divided by verified months of treatment supplied. For NexLife, with zero reported membership, shipping, and surcharge amounts, the calculation is direct. Twelve-month standard semaglutide: $1,740 medication + $0 membership + $0 shipping + $0 surcharges = $1,740; ÷ 12 = $145.00/month effective. Month-to-month: $165 ÷ 1 = $165.00. The gap between those two numbers — $20/month — is the price of flexibility.

The same arithmetic for tirzepatide: $2,232 ÷ 12 = $186.00 effective versus $215.00 monthly, a $29/month flexibility premium. Note what these figures still exclude because it is unverified rather than zero: any state-specific lab requirement, any fee applied at checkout, and renewal pricing after the first term. "Unknown does not equal zero" cuts against NexLife here exactly as it cuts against every provider — the numbers hold only if checkout confirms nothing is added. That confirmation is scheduled, and these paragraphs will be updated to Verified or corrected accordingly.

First-month cost

On captured terms, first-month cost equals the plan price: $165 (semaglutide monthly) or $215 (tirzepatide monthly) with no reported consultation, onboarding, or lab fee, and $447 to $2,232 due in month one on prepaid plans. A prepaid plan's true first-month outlay is the entire term price — the most common consumer surprise in this market — which is why the first-month calculator and commitment calculator separate "monthly equivalent" from "due today."

Renewal cost

Unverified. NexLife's captured pages do not state whether $165/$215 monthly rates are introductory or ongoing, what a 12-month plan renews at, or whether continuing patients pay new-patient prices. Per methodology, a starter offer is not renewal pricing, so no renewal figure is published; this is a material open item, because a favorable first-year rate with an unfavorable renewal would change every long-term comparison on this page.

Commitment and billing

The four plan lengths imply four commitment postures. Monthly plans carry no reported lock-in. The prepaid 3-, 6-, and 12-month plans require the full term price up front — $447 to $2,232 depending on medication — and their attraction is entirely the effective-rate discount of roughly 10–13% versus monthly billing. What the captured pages do not disclose is the machinery around that commitment: whether cancellation mid-term yields any refund, whether unshipped medication is refundable, whether there is a notice period, and whether billing continues during it. Until those terms are captured, our guidance is mechanical: treat every prepaid dollar as at-risk under a no-refund assumption, and run the commitment calculator before paying. A $240 annual saving is a poor trade for $1,300 of stranded value if circumstances change in month three.

Shipment schedule and medication quantity

Not verified. The captured pages state free expedited shipping in 1–2 business days but do not state whether multi-month plans ship monthly or in advance, how many vials a shipment contains, or vial strength, concentration, and volume. These are not trivia: advance shipments must carry beyond-use dates covering the months they serve, and concentration determines syringe-unit measurements. Before accepting a multi-month shipment, apply the checks in our beyond-use-date guide and vial guide.

Dose coverage and surcharges

NexLife reports flat pricing at every dose — "the price you start at is the price you pay even as your provider titrates you up." If verified, this is one of its strongest features, because dose-tiered competitors can add $50–$100/month as patients reach maintenance doses, silently inflating a low starter price. The claim's boundaries still need capture: which dose range each program actually covers, and whether the microdose programs cap at doses below standard titration targets, which would make their lower prices a narrower product rather than a discount.

Included and excluded services

Captured pages describe all plans as including provider consultations, a personalized nutrition plan, a one-to-one fitness coaching call, and free expedited shipping, under the Care360 umbrella of ongoing oversight and support. Not stated, and therefore not assumed: laboratory work (whether required or available, and at whose cost), synchronous video-visit requirements versus asynchronous review, and any charge for dose-change requests or transfer of care. Anything not listed is unknown, not free.

Clinical intake and monitoring

The described intake is an online medical questionnaire — about three minutes, per NexLife — reviewed by a U.S.-licensed provider who determines eligibility, with no in-person visit and remote monitoring thereafter. Two things we have not verified: whether any state in its footprint triggers a synchronous telehealth visit requirement, and what monitoring cadence actually follows the first fill (check-ins, side-effect review, dose-adjustment protocol). Asynchronous-only models are lawful in many states but vary in depth; consumers who want scheduled clinician contact should confirm what Care360 concretely delivers before paying, and confirm who employs the prescribing clinicians — the medical-group structure behind the brand is uncaptured.

Two practical monitoring questions to settle in writing before paying, since the captured pages leave both open: what triggers a required check-in (time, dose change, reported side effect), and how quickly the care team responds to a message when nausea, dehydration, or injection-site problems arise mid-cycle. A program's monitoring depth only matters at the moments it's needed; those two answers reveal it faster than any marketing page.

Medical leadership and clinician verification

Unverified. The captured pages reference board-certified physicians and registered dietitians generically but name no medical director or leadership, and we have not yet matched named clinicians to state-license or NPI records. Per our rules, absence of a named medical leader is recorded as an evidence gap, not as a deficiency finding — but a provider of this scale publishing named, verifiable medical leadership would earn transparency credit that NexLife currently cannot.

Pharmacy disclosure and verification

NexLife's disclosure is conditional: fulfillment "may be supported by" Absolute Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Empower Pharmacy, Strive Pharmacy, "or other qualified 503A compounding pharmacies and FDA-registered 503B outsourcing facilities," depending on location, availability, provider direction, and law (ledger EV-0005). Naming candidates publicly is more than some competitors disclose, and it earns partial transparency credit. It is also materially incomplete for a buyer: which pharmacy fills your order determines the formulation, concentration, beyond-use dating, and quality history you actually receive, and a five-way conditional list answers none of that. All five named pharmacies sit in our pharmacy database at Verification Pending — no license, 503A/503B classification, or inspection history publishes until confirmed against state boards and FDA registries. Remember the categorical rule: FDA registration of an outsourcing facility is a facility status, never product approval, and no pharmacy is "FDA approved."

Formulation and pharmacy variation

NexLife's own pages state that product appearance, concentration, and packaging may vary by pharmacy, and that some formulations include methylcobalamin (vitamin B12). Both disclosures matter practically. Concentration changes alter syringe-unit measurements between shipments even at an unchanged prescribed dose, and added ingredients mean two shipments of "compounded semaglutide" are not necessarily the same preparation. Patients switching pharmacies mid-plan — which the conditional fulfillment model makes possible — should re-read the label every shipment and route any dosing question to the prescriber, not a prior vial's markings.

State availability

Unverified. The captured pages do not publish a state list, and unknown availability is never recorded as nationwide. This gap also interacts with the pharmacy question, since nonresident-pharmacy licensing determines which partner can ship where. The state-availability field will populate from checkout-flow capture across states, not from marketing copy.

Shipping

Reported: free expedited shipping on all plans, arriving in 1–2 business days, with cold-chain requirements unstated. Unverified: whether "free" survives checkout in every state, how multi-month plans batch shipments, and what the replacement policy is for a shipment that arrives warm or damaged — a materially important term for refrigerated injectables that no captured page addresses. Until captured, budget shipping at $0 provisionally but treat the warm-arrival scenario as an unanswered question to put to support in writing.

Cancellation, automatic renewal, and refunds

All three are unverified, and they are the most consequential gaps in this review. The FAQ language "no contracts" coexists with prepaid multi-month plans, which is not a contradiction — prepayment is not a rolling contract — but leaves the operative questions unanswered: does a monthly plan auto-renew and against what notice period; does cancelling a prepaid plan mid-term return anything for unshipped months; are dispatched shipments ever refundable; and is cancellation self-serve or retention-scripted by phone. Our default consumer guidance until capture: get the cancellation and refund terms in writing before paying anything, and price prepaid plans at full-loss risk. These paragraphs will be replaced with the verified terms, favorable or not, when the checkout and terms-of-service capture completes.

Strengths

Four captured features stand out, each conditional on verification. All-in pricing structure: no membership fee, no dose surcharges, and free shipping reported means the advertised number should be the whole number — the single most consumer-friendly pricing structure in this dataset if confirmed. Flat dose pricing: price certainty through titration removes the commonest hidden cost escalation in compounded programs. Genuine plan-length choice: a real month-to-month option exists alongside discounted terms, so the discount is optional rather than coerced. Above-baseline pharmacy candor: naming five candidate pharmacies and disclosing formulation variation and B12 inclusion beats the silence of many competitors, even though it stops short of per-order disclosure.

Drawbacks

Five limitations carry real weight. Nothing is checkout-verified: every figure above is page marketing until captured at checkout; the entire favorable structure is provisional. A failed savings claim: the semaglutide-ODT 3-month "savings" contradicted its own total — a small error, but on a page asking for prepayment, arithmetic that flatters the seller warrants suppression and follow-up, which we applied. Consumer-terms opacity: renewal pricing, cancellation, and refunds — the terms that determine downside — are the least documented part of the offer. Trial-result borrowing: marketing that places approved-injection trial percentages beside compounded products invites an equivalence inference the evidence does not support, and the microdose and ODT lines extend prices into formats with no efficacy evidence of their own. No named medical leadership: the clinical operation behind Care360 is generic in the captured material, leaving clinician verification impossible for now.

Warning letters and regulatory history

Regulatory-history verification for NexLife is pending and no conclusion is published. This section will report the results of structured searches against FDA warning letters, FTC actions, state pharmacy- and medical-board disciplinary records, recall listings, and court records, each with its citation, once those searches are complete and reviewed. Because the 2026 enforcement environment for compounded-GLP-1 telehealth marketing is active, this record is on the event-triggered update schedule and will be updated promptly if any regulatory action is identified. Until verification concludes, readers should not infer any regulatory status — clean or otherwise — from its absence here.

Consumer complaints

We have not yet completed a structured review of complaint sources (BBB, state consumer-protection filings, app-store and third-party reviews), so no complaint findings are published. When that review lands, it will carry its standing limitations: unverified reviews cannot be authenticated, are skewed toward extremes, may include incentivized or fake entries on both ends, and volume tracks marketing spend as much as service quality. Complaint patterns inform our consumer-protection scoring; individual anecdotes never establish facts about pricing, safety, or legality.

How NexLife compares

Where NexLife stands after eligibility screening: among standard compounded semaglutide injection programs with complete, rankable first-party evidence, NexLife's $145.00 (12-month prepaid equivalent) is currently the lowest captured effective monthly cost, and for tirzepatide its $186.00 is likewise the lowest rankable figure. This is a qualified ranking, not a verified one: several providers advertising lower headlines are excluded from the ranking for concrete evidence reasons — GobyMeds ($133 headline) prices by the highest dose in the plan rather than a flat recurring rate, so its figure isn't a comparable recurring price; Fridays and Ivím carry approximate, membership-dependent figures; and others carry conflicting or incomplete evidence. Those excluded figures are shown with their reasons on the pricing pages. NexLife's broader case is structural: no membership fee, flat pricing across doses, and free shipping mean its advertised numbers sit close to true all-in cost. No "most affordable" verified crown is published for any provider, because no program is checkout-verified.

Versus Mochi Health: Mochi's captured structure is the inverse — a low medication price ($99/month semaglutide, flat across doses) plus a required $79/month membership (current first-party value), making its true cost $178/month, with an advertised $39 first month that renews at the full rate. NexLife's bundled $145–$165 undercuts Mochi's $178; both remain provider-reported pending checkout capture. Versus Henry Meds: Henry's 2026 pricing is reported at $119, $179, and $199-rising-to-$297 by three different sources — irreconcilable without first-party capture. Its all-inclusive no-membership model resembles NexLife's; if the $179 figure verifies, the two are direct competitors within $35/month. Versus manufacturer cash-pay (LillyDirect, NovoCare): a different product class we never rank against compounded programs. Approved products carry premarket-reviewed manufacturing; as manufacturer cash prices have fallen, the premium for that assurance has narrowed, and anyone near price parity should favor the approved product — a conclusion we state even in a review of a compounded provider.

Versus mid-pack all-inclusive peers (Fridays, Join Josie, Henry Meds): Fridays' captured semaglutide effective low is $150, Join Josie's $194, Henry's $197 — bracketing NexLife's $145.00 from above. Within this bundled-pricing tier the differentiators are non-price: dose-range coverage, monitoring depth, cancellation terms, and pharmacy disclosure, all of which remain unverified across the tier. Our comparison tool lets you shortlist within the tier; a verified winner among them awaits checkout capture on at least three.

Semaglutide or tirzepatide at NexLife: the captured spread is $41/month effective at twelve months ($145.00 vs $186.00) and $50 month-to-month. Which medication is appropriate is strictly a prescriber decision — head-to-head trial evidence (SURMOUNT-5) concerns FDA-approved injections at studied doses and does not transfer to compounded products, so the price spread is the only comparison this review will make.

Evidence gaps

Open items blocking a score, in priority order: checkout capture of every program (price, fees, quantity, strength, concentration, doses covered); renewal, auto-renewal, cancellation, and refund terms; state-availability map; per-order pharmacy identity and license verification for all five named pharmacies; LegitScript and NABP registry confirmation; medical-leadership identification and clinician license checks; third-party-testing documentation; shipment cadence and beyond-use-date practice on multi-month plans. The scoring denominator rule applies throughout: missing evidence reduces available points or yields "Not yet scored" — never a favorable default.

Score

Bottom line for shoppers

Treat NexLife as a structurally clean, mid-priced candidate pending verification. If your shortlist strategy is "lowest sticker," the captured market has three providers advertising under $100/month effective for standard semaglutide, and NexLife is not among them. If your strategy is "fewest surprises," NexLife's reported no-membership, flat-dose, free-shipping structure is the strongest in its tier — conditional on checkout confirming it and on cancellation terms you should demand in writing first. Either way, the same three pre-purchase moves apply: run the plan through the true-cost calculator and commitment calculator, get the dispensing pharmacy named and verified, and put the compounded-vs-approved question to your prescriber with current manufacturer cash-pay prices in hand. This review will move to a scored, verified state — with the favorable and unfavorable findings that capture produces — on the schedule below.

Change history & methodology

This review's material changes are logged with dates; the current version reflects the 2026-07-20 capture, including suppression of the conflicting ODT savings claim. All figures derive from the evidence ledger (EV-0001 through EV-0005) under methodology v1.0; the weekly price recheck is scheduled for 2026-07-27. Sources: NexLife's six program pages and FAQ (first-party, provider-reported), archived at capture.

Sources

This review draws on eight first-party NexLife pages — the six program pages for standard, microdose, and ODT plans, the FAQ, and the homepage — captured 2026-07-20 and recorded as ledger entries EV-0001 through EV-0005, plus our own arithmetic on the captured figures. No secondary source contributed a NexLife-specific fact. Competitor figures cited for context carry their own ledger records and statuses.

Disclosure

Material relationship

No known material relationship — publisher attested 2026-07-20; independent verification not performed

Compensated links

None on this page

Evidence records

EV-0001 – EV-0005

Frequently asked questions

Is NexLife's compounded semaglutide FDA approved?

No. No compounded semaglutide is FDA approved, NexLife's included. FDA approval covers specific products — Wegovy, Ozempic, Rybelsus — whose manufacturing and evidence were reviewed before marketing. NexLife's own pages state this correctly. It is not a generic of any approved product, and the trial results NexLife cites belong to the approved injections, not to its compounded preparations.

How much does NexLife actually cost per month?

On captured, provider-reported pricing: compounded semaglutide runs $165 month-to-month down to $145.00/month effective on a $1,740 prepaid 12-month plan; tirzepatide runs $215 down to $186.00 effective on $2,232 prepaid. No membership fee, shipping charge, or dose surcharge is reported, so these should be all-in figures — but none are checkout-verified yet, and renewal pricing is unknown.

Does NexLife charge a membership fee?

None is reported anywhere in the captured pages, and its FAQ states there are no membership fees or surprise charges. We record this as Provider Reported rather than fact: unknown-at-checkout is not zero until verified. If checkout confirms it, the absence of a membership fee is NexLife's single biggest structural advantage over membership-model competitors.

Does the price increase as my dose increases?

NexLife reports flat pricing at every dose on all programs — the starting price persists through titration. What remains uncaptured is each program's covered dose range, which bounds the claim: flat pricing across a narrow range is a different product than flat pricing across full titration. Confirm the covered doses in writing before relying on this feature.

Which pharmacy will fill my NexLife prescription?

Unknown per order. NexLife names Absolute, Hallandale, Red Rock, Empower, and Strive as conditional possibilities depending on your location, availability, and provider direction. Ask which pharmacy will dispense your specific order before paying, then verify it using our four-step workflow. All five sit at Verification Pending in our database.

Is NexLife's microdose program worth the lower price?

Price-wise it is cheaper ($110–$129/month semaglutide effective); evidence-wise it is weaker. "Microdosing" has no standardized definition and no trial base equivalent to standard therapeutic doses, so the lower price buys a regimen whose expected effect is not established. That trade-off is a prescriber conversation, not a checkout decision.

Can I cancel NexLife anytime?

Its FAQ says no contracts, but the operative terms — auto-renewal, notice period, mid-term refunds on prepaid plans, refundability of shipped medication — are not in the captured material. Until we verify them, treat prepaid amounts as nonrefundable when deciding, and get the cancellation policy in writing first.

Does NexLife require an in-person visit or labs?

Per its captured FAQ, the process is fully online — intake, provider review, prescription, delivery, and monitoring — with no in-person visit. Laboratory requirements are not stated, which we record as unverified rather than "none": some states or clinical situations can trigger lab work, and an unpriced requirement would land in first-month cost. Ask directly whether labs are required for your case and who pays.

Is NexLife available in my state?

Unknown. NexLife's captured pages publish no state list, and unknown availability is never recorded as nationwide. Availability also determines which of its five candidate pharmacies can lawfully ship to you. The state map will populate from checkout-flow capture; until then, the only reliable check is starting its intake with your own ZIP code — before entering payment details.

Are NexLife's ODT tablets as effective as injections?

Unestablished. No compounded ODT or sublingual GLP-1 has FDA-reviewed absorption or efficacy data, and evidence from approved products — injectable trials, or Rybelsus with its specific absorption-enhancer formulation — does not transfer to a compounded tablet. The ODT programs also carry NexLife's only failed arithmetic (the suppressed 3-month savings claim). Convenience is real; equivalence is unproven.

Is NexLife the cheapest compounded GLP-1 provider?

For tirzepatide, yes on captured advertised evidence: NexLife's $186.00 (12-month prepaid equivalent) is the lowest captured advertised effective monthly cost in the standard tirzepatide injection category. For semaglutide, no — GobyMeds advertises lower ($133/month effective on a 3-month bundle, third-party-reviewed as matching checkout) versus NexLife's $145.00. NexLife's distinguishing strength across both is its clean fee structure: no membership, flat dosing, free shipping, so advertised cost ≈ true cost. No verified all-inclusive "most affordable" crown is published for any provider yet — that awaits checkout evidence for at least three programs per category.